Latest news

ABAC AbYlink Acteon ADC afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections altis labs Antibody Drug Conjufates Aspen Award BC Platforms Biocartis Campus après-demain CARB-X Carbonex CDiff Challenge Debiopharm-Inartis Clinical Trials Coorpacademy CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0328 Debio 0432 Debio 0507 Debio 0513 Debio 0517 Debio 0532 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0633 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1124 SCLC Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1454S Debio 1460 Debio 1561 Debio 1562 Debio 4126 debio 4326 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Academy Debiopharm Chair in Family Philanthropy Debiopharm Life Sciences Award Debiovision Degraducer Dexa Medica Diagnoplex EPFL EPI-hNE4 FibroTrap Fosanis fuze Galiena Capital genepoc genialis Groupe Bertrand H3 Pharma Haut-Lac HES-SO Huperzine-A IDEAL Iktos Immunexpress InnoCentive Japanese Cancer Research Association JCA-Mauvernay Award Kaiku Health KeyLemon little green house MedaSystems Mekonos Moapar Multilink Muscular Dystrophy naratuximab emtansine (Debio 1562) NeoVacs Novadiscovery nucleai Oncolifestyle Oncology Chair oncomfort Oxaliplatin paper.li PLGA Prix Debiopharm/Valais revogene Skiioo Spinomix Strategikon Swiss Biotech Association Téléthon Tremelimumab Triptorelin VeriSIM Life VivoSense Wazoku WhiteLab Genomics xevinapant YonaLink

November 18, 2014

Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona

May 28, 2014

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

June 4, 2013

Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies

September 7, 2011

Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…